✦ LIBER ✦

247 ORAL BRAF V600E confers resistance to cetuximab or panitumumab in metastatic colorectal cancer

✍ Scribed by F. Di Nicolantonio; M. Martini; F. Molinari; A. Sartore Bianchi; S. Arena; P. Saletti; L. Mazzucchelli; M. Frattini; S. Siena; A. Bardelli

Book ID: 119599404
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 64 KB
Volume: 6
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(08)72181-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

6113 BRAF V600E mutation and Amphireguli

6113 BRAF V600E mutation and Amphiregulin (AR) immunohistochemical expression in the prediction of benefit from cetuximab plus irinotecan in KRAS wild-type metastatic colorectal cancer (mCRC) patients

✍ Cremolini, C.; Loupakis, F.; Perrone, G.; Ruzzo, A.; Rulli, E.; Bencardino, K.; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 66 KB

KRAS codon 61, 146 and BRAF mutations pr

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer

✍ Loupakis, F; Ruzzo, A; Cremolini, C; Vincenzi, B; Salvatore, L; Santini, D; Masi 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 295 KB

No Survival Benefit from Adding Cetuxima

No Survival Benefit from Adding Cetuximab or Panitumumab to Oxaliplatin-Based Chemotherapy in the First-Line Treatment of Metastatic Colorectal Cancer in KRAS Wild Type Patients: A Meta-Analysis

✍ Zhou, Si-wei; Huang, Yuan-yuan; Wei, Ying; Jiang, Zhi-min; Zhang, Yuan-dong; Yan 📂 Article 📅 2012 🏛 Public Library of Science 🌐 English ⚖ 533 KB